Approach to Risk Assessment and Management of ASCVD
A 38-year-old white man is referred to the lipid clinic for optimization of his cardiovascular (CV) health. He has history of obesity and hypertension (HTN).
View ArticleEagle’s Eye View: What are the Benefits of Inclisiran in Patients With...
In this week’s View, Dr. Eagle explores a UK Biobank study on triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease. He then discusses the risk of...
View ArticleAtheroma Regression in Response to Lipid-Lowering Therapy
What are the rates, determinants, and prognostic implications of triple regression in patients presenting with acute myocardial infarction (AMI) and treated with high-intensity lipid-lowering therapy?
View ArticleACC Featured Jobs For November 2023
Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!
View ArticleVERVE-101: CRISPR-Based Gene Editing Therapy Shows Promise in Reducing LDL-C...
A single infusion of a CRISPR-based gene editing therapy significantly reduced LDL-C and PCSK9 levels in patients with heterozygous familial hypercholesterolemia (HeFH), based on findings from the...
View ArticleSingle Dose of Lepodisiran Shows Promise in Lowering Lp(a) Over an Extended...
A single subcutaneous injection of lepodisiran, an siRNA targeting mRNA for the LPA gene, substantially lowered lipoprotein(a), or Lp(a), below baseline levels for 48 weeks, according to new...
View ArticleREMAIN-2: Long-Term Efficacy and Safety of Recaticimab in Patients With...
Findings from the REMAIN-2 trial presented Nov. 12 at AHA 2023 demonstrated the long-term efficacy and safety of add-on recaticimab as a therapeutic option in patients with non-familial...
View ArticleACC Cardiology Hour | AHA 2023
A long-standing resource for busy cardiovascular professionals, ACC Cardiology Hour offers multidisciplinary expert discussion on top clinical trials released during cardiology's biggest meetings.
View ArticleInflammation and Cholesterol as Predictors of CV Events
Is residual inflammatory risk assessed by high-sensitivity C-reactive protein (hs-CRP) as strong a predictor of future cardiovascular events (CVEs) as is residual risk assessed by low-density...
View ArticleEagle’s Eye View: What is the role of inflammation as a predictor of...
In this week’s View, Dr. Eagle explores the role of inflammation as a predictor of coronary risk. He then discusses the safety and efficacy of renal denervation in patients taking antihypertensive...
View ArticlePrimary Prevention of Subclinical Atherosclerosis in Young Adults
The following are key points to remember from a review on primary prevention of subclinical atherosclerosis in young adults.
View ArticlePrioritizing Health | Prevention: Early is Better, But It’s Never Too Late
We're never too young for diabetes to substantially increase the risk of atherosclerotic cardiovascular disease (ASCVD) and we're never too old to experience the benefits of lipid-lowering therapy...
View ArticleLong-Term Safety of Inclisiran for Treatment of Hypercholesterolemia
What is the evidence on the long-term safety profile of inclisiran for treatment of hypercholesterolemia?
View ArticleBempedoic Acid for LDL-Lowering: Case Challenges
This activity was planned with a goal to enable participants to learn best practices when prescribing bempedoic acid to the statin intolerant patient.
View ArticleEagle’s Eye View: What is the Safety and Tolerability of Inclisiran in...
In this week’s View, Dr. Eagle explores longitudinal changes in pulmonary artery pressure late in life using data from the ARIC study.
View ArticleRole of Polyunsaturated Fat in Modifying CVD Risk
Does dietary intake of polyunsaturated fats (PUFAs) modify the cardiovascular disease (CVD) risk associated with a family history of CVD?
View ArticleTop 10 ACC News Stories of 2023
The top ACC news stories of 2023 included news about ACC's latest clinical documents, health policy news about the 2024 Medicare Physician Fee Schedule rule and new Global Burden of Cardiovascular...
View ArticleTop Clinical Content for 2023
The most popular clinical content items of 2023, developed by the ACC.org Editorial Board, including the ACC Member Section Editorial Teams and the E-Learning Team.
View Article2023 Top Journal Scans and Clinical Trials
In 2023, we continued to see advances in global health technology. These technologies provide a means to prevent, diagnose and treat cardiovascular disease and may also hold the keys to addressing...
View ArticleACCEL Lite: Top Takeaways from 2023: Preventive Cardiology with Noel Bairey...
In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD, FACC discuss the top takeaways from 2023 in Preventive Cardiology including the CLEAR-Outcomes, REPRIEVE, and SELECT trials.
View Article
